CA3224741A1 - Ligand-drug conjugate and use thereof - Google Patents

Ligand-drug conjugate and use thereof Download PDF

Info

Publication number
CA3224741A1
CA3224741A1 CA3224741A CA3224741A CA3224741A1 CA 3224741 A1 CA3224741 A1 CA 3224741A1 CA 3224741 A CA3224741 A CA 3224741A CA 3224741 A CA3224741 A CA 3224741A CA 3224741 A1 CA3224741 A1 CA 3224741A1
Authority
CA
Canada
Prior art keywords
conjugate compound
pharmaceutically acceptable
acceptable salt
date received
date recue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3224741A
Other languages
English (en)
French (fr)
Inventor
Baohua Robert HUANG
Wei Tan
Guitao WANG
Jun Shao
Shengfei MAO
Zhongbo WANG
Longjun GU
Gang Qian
Tingting BU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherent Biopharma (Suzhou) Co Ltd
Original Assignee
Coherent Biopharma (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherent Biopharma (Suzhou) Co Ltd filed Critical Coherent Biopharma (Suzhou) Co Ltd
Publication of CA3224741A1 publication Critical patent/CA3224741A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3224741A 2021-06-25 2022-06-24 Ligand-drug conjugate and use thereof Pending CA3224741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/102377 2021-06-25
CN2021102377 2021-06-25
PCT/CN2022/101108 WO2022268202A1 (zh) 2021-06-25 2022-06-24 配体药物偶联物及其应用

Publications (1)

Publication Number Publication Date
CA3224741A1 true CA3224741A1 (en) 2022-12-29

Family

ID=84544230

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3224741A Pending CA3224741A1 (en) 2021-06-25 2022-06-24 Ligand-drug conjugate and use thereof

Country Status (11)

Country Link
US (1) US20240358843A1 (enExample)
EP (1) EP4360654A4 (enExample)
JP (1) JP2024523524A (enExample)
KR (1) KR20240025514A (enExample)
CN (1) CN117693365A (enExample)
AU (1) AU2022296571A1 (enExample)
CA (1) CA3224741A1 (enExample)
IL (1) IL309543A (enExample)
MX (1) MX2023015286A (enExample)
TW (1) TW202317199A (enExample)
WO (1) WO2022268202A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
KR20240142405A (ko) * 2021-11-17 2024-09-30 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체-약물 복합체 및 그의 용도
WO2024131944A1 (zh) * 2022-12-23 2024-06-27 同宜医药（苏州）有限公司 药物组合物及其制备方法和用途
IL322887A (en) * 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof
CN121001746A (zh) * 2023-04-26 2025-11-21 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478543A1 (en) * 2001-10-26 2003-04-26 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
AU2013288932A1 (en) * 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
CN104784699B (zh) * 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
CA2987322C (en) * 2015-08-11 2020-02-11 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
CN107412794B (zh) * 2017-04-17 2019-01-04 中国医学科学院北京协和医院 双靶点显像分子探针及其制备方法和应用
US20210353652A1 (en) * 2018-06-04 2021-11-18 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
JP7546574B2 (ja) * 2019-01-30 2024-09-06 コヒレント バイオファーマ （スーチョウ），リミテッド 二重リガンド薬物コンジュゲート及びその使用

Also Published As

Publication number Publication date
US20240358843A1 (en) 2024-10-31
JP2024523524A (ja) 2024-06-28
AU2022296571A1 (en) 2023-12-14
WO2022268202A1 (zh) 2022-12-29
EP4360654A4 (en) 2026-07-15
KR20240025514A (ko) 2024-02-27
TW202317199A (zh) 2023-05-01
EP4360654A1 (en) 2024-05-01
CN117693365A (zh) 2024-03-12
MX2023015286A (es) 2024-04-03
IL309543A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
CN113453720B (zh) 双配体药物偶联体及其用途
US20230000993A1 (en) Silicon based drug conjugates and methods of using same
EP4360654A1 (en) Ligand-drug conjugate and use thereof
AU2022220512A9 (en) Bioactive substance conjugate, preparation method therefor and use thereof
CA3024371C (en) Multi-arm polymeric targeting anticancer conjugate
CA3198788A1 (en) Camptothecine antibody-drug conjugates and methods of use thereof
HK1243339A1 (zh) 作为免疫调节剂的1，3，4-恶二唑和噻二唑化合物
US20180078656A1 (en) Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
WO2021046426A1 (en) Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
AU2023285718A1 (en) A camptothecin drug and its antibody conjugate thereof
JP6947909B2 (ja) マルチアーム標的抗がんコンジュゲート
EP2824108B1 (en) Tetracyclic anthraquinone derivatives
EP4659764A1 (en) Linker drug, and preparation method and use of antibody-drug conjugate thereof
US20040037775A1 (en) Leukocyte internalized peptide-drug conjugates
CN110551102B (zh) Alk共价抑制剂及其用途
CN111909240A (zh) 一种pd-1/pd-l1多肽类抑制剂及其医药用途
AU2017200704B2 (en) Modulation of chemosensory receptors and ligands associated therewith
CN116018160B (zh) 一种包含sn38的抗体药物偶联物中间体及其制备方法
CN120303002A (zh) 包含抗肿瘤剂的聚合化合物
CN114957346B (zh) 一种抗体偶联剂及其制备方法与应用
HK40108260A (en) Ligand-drug conjugate and use thereof
CA3127903A1 (en) Bi-ligand drug conjugate and use thereof
HK40052006A (en) Bi-ligand drug conjugate and use thereof
CN104961800A (zh) 多肽--蒽环类衍生物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260624

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260624

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260624